Carmen Argmann

The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…

Vedolizumab (VDZ) is a monoclonal antibody that targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC) and Crohn’s disease, its mode of action (MOA) remains unclear…

BACKGROUND: Multiple studies have identified interleukin (IL)-1 proteins (IL-1α, IL-1β) as playing a key role in intestinal inflammation, including the expansion of IL-1 expressing cells as a hallmark of severe and anti-TNFα non-responsive inflammatory bowel disease (IBD)…